Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Aldeyra Therapeu
(NQ:
ALDX
)
5.360
-0.080 (-1.47%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Aldeyra Therapeu
< Previous
1
2
3
4
5
6
Next >
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease
October 03, 2024
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
September 05, 2024
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap
August 08, 2024
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 Dry Eye Chamber Clinical Trial of Reproxalap
August 07, 2024
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable
June 20, 2024
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease
June 13, 2024
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics to Host Investor Roundtable Q&A
June 12, 2024
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference
May 29, 2024
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease
May 08, 2024
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day
April 25, 2024
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024
April 18, 2024
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease
March 28, 2024
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
ALDEYRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Aldeyra Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
February 09, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 06, 2024
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases
January 04, 2024
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic Dermatitis
December 19, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis
December 18, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease
November 27, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Inc. (NASDAQ: ALDX) is One of Wednesday Morning’s Most Active Stocks
November 01, 2023
Via
Investor Brand Network
Aldeyra Therapeutics Enters into Exclusive Option Agreement with AbbVie for License to Develop and Commercialize Reproxalap
November 01, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
NASDAQ:ALDX Long Term Investor Alert: Investigation over Potential Wrongdoing at Aldeyra Therapeutics, Inc.
October 17, 2023
San Diego, CA -- (SBWIRE) -- 10/17/2023 -- Certain directors of Aldeyra Therapeutics, Inc. are under investigation over possible breaches of fiduciary duties.
Via
SBWire
DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 29 Deadline in Securities Class Action - ALDX
September 29, 2023
WHY: NEW YORK, NY - (NewMediaWire) - September 29, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between March...
Via
TheNewswire.com
Topics
Lawsuit
Exposures
Financial
Legal
DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 29 Deadline in Securities Class Action - ALDX
September 29, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aldeyra Therapeutics, Inc. (ALDX)
September 28, 2023
From
The Law Offices of Frank R. Cruz
Via
Business Wire
ALDEYRA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Aldeyra Therapeutics, Inc. and Encourages Investors to Contact the Firm
September 27, 2023
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
Deadline Alert: ALDX Investor Alert: Contact Bronstein, Gewirtz & Grossman, LLC to Actively Participate in the Aldeyra Therapeutics, Inc. Class Action Lawsuit
September 26, 2023
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
NASDAQ: ALDX Investor Alert: Deadline on September 29, 2023 in Lawsuit Against Aldeyra Therapeutics, Inc.
September 25, 2023
San Diego, CA -- (SBWIRE) -- 09/25/2023 -- The Shareholders Foundation announced that a deadline is coming up on September 29, 2023 in the lawsuit filed for certain investors of Aldeyra Therapeutics,...
Via
SBWire
Topics
Lawsuit
Exposures
Financial
Legal
ALDX DEADLINE ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important September 29 Deadline in Securities Class Action – ALDX
September 25, 2023
From
The Rosen Law Firm PA
Via
GlobeNewswire
ALDX FINAL DEADLINE FRIDAY: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important September 29 Deadline in Securities Class Action - ALDX
September 23, 2023
WHY: NEW YORK, NY - (NewMediaWire) - September 23, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between March...
Via
TheNewswire.com
Topics
Lawsuit
Exposures
Financial
Legal
ALDX FINAL DEADLINE FRIDAY: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important September 29 Deadline in Securities Class Action - ALDX
September 23, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.